Valeri C Robert, Ragno Gina, Veech Richard L
Naval Blood Research Laboratory, 195 Bournehurst Drive, Plymouth, MA 02360, USA.
Artif Cells Blood Substit Immobil Biotechnol. 2006;34(6):601-6. doi: 10.1080/10731190600974087.
Hemoglobin based oxygen carriers (HBOC) are resuspended in "excipients" consisting of Ringer's D,L-lactate containing antioxidants to prevent methemoglobin formation during storage. Investigators have reported cardiac arrhythmias following infusion of Ringer's D,L-lactate solution. Studies have shown that D-lactate stimulates human granulocytes to generate oxygen free radicals and L-lactate inhibits glycolysis. Patients receiving HBOC in Ringer's D,L-lactate excipient are also resuscitated or hemodiluted with Ringer's lactate solution. Oxygen-free radicals generated by Ringer's D,L-lactate and HBOC may oxidize nitric oxide in endothelial cells, causing the vasoconstrictor effects reported following HBOC infusion, and activate NF-kappab and the apoptotic cascade. The combination of Ringer's D,L-lactate and HBOC in Ringer's D,L-lactate excipient may be responsible for the severe adverse events observed in clinical studies of HBOC.Veech has recommended replacing the 27 mM of lactate in Ringer's with 27 mM D-betahydroxybutyrate (BHB). BHB reduces the generation of oxygen free radicals by mitochondria and human granulocytes.
基于血红蛋白的氧载体(HBOC)悬浮于由含抗氧化剂的林格氏D,L-乳酸盐组成的“辅料”中,以防止储存期间高铁血红蛋白的形成。研究人员报告了输注林格氏D,L-乳酸盐溶液后出现的心律失常。研究表明,D-乳酸盐刺激人类粒细胞产生氧自由基,而L-乳酸盐抑制糖酵解。在林格氏D,L-乳酸盐辅料中接受HBOC的患者也用林格氏乳酸盐溶液进行复苏或血液稀释。林格氏D,L-乳酸盐和HBOC产生的氧自由基可能会氧化内皮细胞中的一氧化氮,导致HBOC输注后报告的血管收缩作用,并激活核因子κB和凋亡级联反应。林格氏D,L-乳酸盐和HBOC在林格氏D,L-乳酸盐辅料中的组合可能是HBOC临床研究中观察到的严重不良事件的原因。维奇建议用27 mM D-β-羟基丁酸盐(BHB)替代林格氏液中27 mM的乳酸盐。BHB可减少线粒体和人类粒细胞产生氧自由基。